Viking Therapeutics, Inc. (VKTX)

Discussion in 'Men's Economics' started by Michael Scally MD, Mar 3, 2018.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Viking Therapeutics, Inc. (VKTX)
    Viking Therapeutics

    VKTX : Summary for Viking Therapeutics, Inc. - Yahoo Finance

    [Basically, a LGND spin-off. IMO, ultimate failure. But a possible trade for profit. Be Careful.

    Our lead clinical program is VK5211, a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery.

    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
     
    J DUGIN likes this.
  2. rugerjitsu

    rugerjitsu Member

    Buy now, and sell after earnings bump this week??
     
  3. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Whoops ...
     
  4. rugerjitsu

    rugerjitsu Member

    Whoops is right! So much manipulation anymore with these types of stocks.
     
  5. rugerjitsu

    rugerjitsu Member

    Boom!!
     
  6. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Riding the shirt tail of MDGL. Profit but be careful. Their drug will not be approved. Nor, can they afford the trials so maybe hope for a buyout [doubtful].
     
  7. Michael Scally MD

    Michael Scally MD Doctor of Medicine

     
  8. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Caveat Emptor ...

    Viking Therapeutics: Sell The Pop On The Sympathy Play
    Viking Therapeutics: Sell The Pop On The Sympathy Play - Viking Therapeutics (NASDAQ:VKTX) | Seeking Alpha

    · VKTX rose as a sympathy play to MDGL as investors surmise that the good data on MGL-3196 increases the probability of success for VK2089.

    · VKTX has had substantial dilution of more than 100% over the last year at much lower prices to today which I think will be a significant overhang.

    · Most perilously, VKTX has an open at-the-market common share purchase agreement with Lincoln Park Capital Fund, a fund known for dilutive financing deals.

    · I expect VKTX's stock to decline in the coming days to a price marginally above where it was prior to Thursday.
     
  9. rugerjitsu

    rugerjitsu Member

    I’ve been keeping my eye on it, but was never remotely close to putting money in it. Just thought I would bump the thread with the recent increase!
     
    Michael Scally MD likes this.
  10. rugerjitsu

    rugerjitsu Member

    bam!!
     
  11. maxmuscle01

    maxmuscle01 Member

    VKTX has developed a sarm or peptide that is improving NASH and fatty liver. If it passes trials it will be worth a fortune. I am keeping up to date on this new drug.